Clinical trials
Acute Promyelocytic Leukemia clinical trials
Below are recruiting acute promyelocytic leukemia clinical trials, each written for real people, not researchers. We’re tracking 251 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06232694Recruiting
Combination therapy for newly diagnosed AML
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Nanjing, JiangsuAges 18–60 - NCT06233526Recruiting
Personalized treatment for children with relapsed or resistant AML
This trial offers a personalized treatment plan for children with hard-to-treat or relapsed acute myeloid leukemia (AML). The plan is based on the unique genetic makeup of the child's cancer and lab tests that find the most effective drugs.
Hangzhou, ZhejiangAges Up to 18 years - NCT05442216RecruitingPhase 2
Study of tagraxofusp, azacitidine, and venetoclax for secondary AML
This trial tests a combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people newly diagnosed with a type of acute myeloid leukemia (AML) that has developed after treatment with certain prior drugs (hypomethylating agents). The goal is to see if this combination is safe and effective.
Miami, FloridaAges 18 years+ - NCT06367673RecruitingPhase 1
NK cell therapy for relapsed or refractory AML
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT06378437RecruitingPhase 1
GLB-001 for blood cancers that have returned or not responded
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
Hefei, AnhuiAges 18 years+ - NCT06483906RecruitingPhase 2
Study of a drug combo and stem cell transplant for high-risk AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06536010Recruiting
Testing a new combination therapy for AML
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
Huai'an, JiangsuAges 18–75 - NCT06594445RecruitingPhase 1
GTB-3650 TriKE for high-risk MDS and relapsed AML
This trial tests a new immunotherapy called GTB-3650 TriKE for people with high-risk MDS or AML that has come back or not responded to treatment. It aims to boost your immune system to fight the cancer.
Minneapolis, MinnesotaAges 18 years+ - NCT06613217RecruitingPhase 1
Oral PCLX-001 for relapsed or refractory AML
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
Houston, TexasAges 18 years+ - NCT06621199RecruitingPhase 2
Three-drug combination for newly diagnosed AML in older adults
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
Hangzhou, ZhejiangAges 60–70 - NCT06634394RecruitingPhase 1
Study of APVO436 for untreated AML patients
This trial tests a new drug called APVO436 for people with a type of acute myeloid leukemia (AML) that has not been treated before. It is for those who cannot receive strong standard chemotherapy due to age, health problems, or organ function issues.
Denver, ColoradoAges 18 years+ - NCT06635681RecruitingPhase 2
Venetoclax plus intensive chemo for AML subtypes
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT06651866RecruitingPhase 1
Study of D-CMG for older adults with new AML
This trial tests a new drug combination called D-CMG for people aged 60–75 who have just been diagnosed with a type of leukemia (AML) and cannot have standard chemotherapy. The goal is to find a safe and effective dose.
Xiamen, FujianAges 60–75 - NCT06656494RecruitingPhase 1
New drug combo for myeloid blood cancers
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
New Haven, ConnecticutAges 18 years+ - NCT06714591RecruitingPhase 1
Testing BL-M11D1 for advanced AML
This trial tests a new drug called BL-M11D1 for people with a type of leukemia that has come back or not responded to standard treatments. It aims to see if the drug is safe and works against cancer cells that have a protein called CD33.
Duarte, CaliforniaAges 18 years+ - NCT06737523RecruitingPhase 1
A new combination therapy for relapsed or refractory AML
This trial tests a three-drug combination for patients whose AML has returned or not responded to prior treatment. It aims to see if adding a new drug (Chiglitazar) to standard treatments (Venetoclax and Azacitidine) can help control the leukemia.
Xiamen, FujianAges 18 years+ - NCT06786533RecruitingPhase 1
CAR-T cells for hard-to-treat AML
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
Houston, TexasAges 12 years+ - NCT06810791RecruitingPhase 3
Comparing Chemotherapy Combos for High-Risk AML
This trial compares three chemotherapy combinations (HVA vs IA/DA or VA) for people with newly diagnosed high-risk acute myeloid leukemia (AML). It aims to find which treatment works better.
Guangzhou, GuangdongAges 18 years+ - NCT06820268RecruitingPhase 1
XS-04 for blood cancers that returned after treatment
This study tests a new drug, XS-04, for people with certain blood cancers (like B-cell lymphoma, AML, or MDS) that have come back or not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors or control the disease.
BeijingAges 18–75 - NCT06827899RecruitingPhase 2
New combination therapy for older adults with untreated leukemia
This trial tests a three-drug combination (venetoclax, chidamide, and azacitidine) followed by another combination (decitabine plus MAG) for older adults with untreated acute myeloid leukemia (AML) who cannot have standard chemotherapy. It aims to offer a gentler but effective treatment option.
Xiamen, FujianAges 60 years+ - NCT07059975RecruitingEarly Phase 1
Better monitoring and treatment for pediatric AML
This trial tests a new way to monitor and treat children and young adults with acute myeloid leukemia (AML) or myeloid sarcoma. It aims to improve outcomes by using personalized treatment adjustments based on how well the disease responds to initial therapy.
Houston, TexasAges 1 month–30 years - NCT07075016RecruitingPhase 3
IDH1 mutation targeted therapy for untreated AML
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
FeldkirchAges 18 years+ - NCT07078591RecruitingPhase 2
Venetoclax with mini transplant for new AML
This trial tests combining the medicine Venetoclax with a mini stem-cell transplant from a partially matched relative for people with newly diagnosed acute myeloid leukemia (AML). It may help control the leukemia while reducing transplant side effects.
BeijingAges 18 years+ - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70
Hear when a new Acute Promyelocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute promyelocytic leukemia?
- Yes. Clin2 currently lists 251 recruiting acute promyelocytic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute promyelocytic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute promyelocytic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.